Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 14 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q3 2026, worth $177.0K in total; no superinvestor holds it.

Holders of 5% or more of AIM

Holders whose latest Schedule 13D or 13G filing reports 5% or more of AIM ImmunoTech Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AIM
HolderLatest formStakeChangeFirst filedLatest filingFiling
Orca Capital AG13G9.90%1.79M sharesNewMay 12, 20261 filingMay 12, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

16 Schedule 13D and 13G filings on AIM ImmunoTech Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AIM
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 27, 20265:14 PM ETIntracoastal Capital, LLCand 2 others13G0.00%0 sharesNewBelow 5%May 20, 2026SEC
May 12, 20264:30 PM ETOrca Capital AG13G9.90%1.79M sharesNewMay 7, 2026SEC
Feb 14, 20254:55 PM ETArmistice Capital, LLCand 1 other13G/A4.99%3.35M shares–Below 5%Dec 31, 2024SEC
Dec 23, 202411:11 AM ETDeutsch Toddand 3 others13D/A2.70%1.72M shares–Below 5%Dec 19, 2024SEC
Dec 17, 2024Deutsch Todd13D/AOld format–––SEC
Nov 14, 2024Armistice Capital, LLC13GOld format–New–SEC
Sep 11, 2024Deutsch Todd13D/AOld format–––SEC
Sep 3, 2024Deutsch Todd13D/AOld format–––SEC
Aug 14, 2024Deutsch Todd13D/AOld format–––SEC
Jul 30, 2024Deutsch Todd13D/AOld format–––SEC
Jul 15, 2024Deutsch Todd13D/AOld format–––SEC
Jan 3, 2024Deutsch Todd13D/AOld format–––SEC
Aug 28, 2023Deutsch Todd13D/AOld format–––SEC
Aug 7, 2023Deutsch Todd13D/AOld format–––SEC
Jul 27, 2023Deutsch Todd13DOld format–New–SEC
Feb 8, 2021Hudson Bay Capital Management LP13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell AIM ImmunoTech Inc. shares.

No Form 144 notices for AIM ImmunoTech Inc. are on file.